Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0725, an antibody targeting CD122 developed independently by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration and is intended to be used to treat autoimmune diseases.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Xiansheng Pharmaceutical (02096.HK) announced that SIM0725, an antibody targeting CD122 developed independently by the Group, has obtained a drug clinical trial approval notice issued by the China National Drug Administration and is intended to be used to treat autoimmune diseases.